Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the bioequivalence of Mylan's paroxetine
hydrochloride 40 mg tablets to GSK's Paxil® 40 mg tablets following a single, oral 40 mg (1 x
40 mg) dose administered under fasting conditions to healthy adult volunteers.